Matrix-assisted laser desorption ionization-time of flight mass spectrometry is not widely used to identify bacteria directly from positive blood culture bottles (BCBs) because of overlong protocols. ...The objective of this work was to develop and evaluate a simple extraction protocol for reliable identification from BCBs. The 10-min protocol was applied over a 5-month period. Direct identifications on day 0 were compared with those obtained from colonies on day 1 log(score) of ≥2. We evaluated a range of seven log(score) thresholds on day 0 from 1.4 to 2.0 to find the lower confidence score that provides the higher percentage of direct identifications without loss of accuracy. With a log(score) threshold of ≥1.5 at day 0, our protocol allowed us to identify 80% of bacteria in 632 BCBs (96% of
, 95% of
, 92% of enterococci, and 62% of streptococci). At least one bacterial species of the mixture was identified in 77% of the polymicrobial samples. The rapidity and reliability of the protocol were factors in its adoption for routine use, allowing us to save up to 24 h in identifying 80% of the bacteria in the BCBs and, thus, to supply useful information to adapt antibiotic therapy when necessary. We currently provide reliable daily direct identifications of staphylococci, enterococci,
,
and beta-hemolytic streptococci.
•ESBL-producing Enterobacteriaceae (ESBL-E) complicated urinary tract infections represent a major health issue.•Data describing efficacy and safety of carbapenem-sparing regimens during prostatitis ...are scarce.•Cefoxitin (FOX) is a cephamycin suitable for ESBL-E prostatitis.•In this prospective study, 23 ESBL-E prostatitis cases were treated with FOX.•Clinical cure rate after 6 months of follow-up was 77%, with no severe adverse events.
The emergence of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) infections requires re-assessment of therapeutic choices. Here we report the efficacy of cefoxitin-based antibiotic therapy for ESBL-E prostatitis. A prospective study including patients with ESBL-E prostatitis resistant to trimethoprim/sulfamethoxazole and fluoroquinolones from January 2014 to March 2016 was conducted. Cefoxitin was administered by continuous infusion for 3 weeks in the case of acute bacterial prostatitis or 6 weeks in the case of chronic bacterial prostatitis (CBP), with intravenous fosfomycin for the first 5 days. Urological investigations were performed to diagnose underlying urinary tract pathology. Clinical and microbiological efficacy were evaluated 3 months (M3) and 6 months (M6) after the end of therapy. A total of 23 patients were included in the study. The median patient age was 74 years (range 48–88 years). Of the 23 infections, 14 (61%) were CBP and 12 (52%) were healthcare-associated infections. The bacteria involved were Escherichia coli in 11 cases, Klebsiella pneumoniae in 10 cases and Klebsiella oxytoca in 2 cases. Clinical cure was observed in 19/23 patients (83%) at M3 and in 17/22 patients (77%) at M6. Urocultures were sterile in 13/23 patients (57%) at M3 and in 9/19 patients (47%) and M6. Urinary colonisation was observed in 6/19 patients (32%) with clinical cure at M3 and 5/14 patients (36%) with clinical cure at M6. No resistance to cefoxitin was detected. Surgical treatment was required for 7/23 patients (30%). In conclusion, cefoxitin-based antibiotic therapy is suitable for difficult-to-treat ESBL-E infections such as prostatitis.
Abstract
We report the first case of Francisella tularensis subsp. holarctica bacteremia after water contamination in France. A 75-year-old man developed septic pneumonic tularemia after a ...near-drowning accident. We highlight the need for a longer incubation time for isolation of F. tularensis from blood cultures.
Celotno besedilo
Dostopno za:
DOBA, IJS, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
The emergence of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) infections requires therapeutic tool reassessment. We report the efficacy of a cefoxitin-based antibiotic therapy ...for ESBL-E prostatitis.
We conducted a prospective study including patients with ESBL-E prostatitis, resistant to cotrimoxazole and fluoroquinolones from January 2014 to March 2016. Cefoxitin was administered by continuous infusion for three weeks in the case of acute prostatitis or six weeks in the case of chronic prostatitis with intravenous fosfomycin for the first five days. Urological investigations were performed to diagnose underlying urinary tract pathology. Clinical and microbiological efficacy was evaluated three months (M-3) and six months (M-6) after the end of therapy.
Twenty-three patients were included; the median age was 74 years 48-88. There were 14/23 (61%) chronic infections and 12/23 (52%) health-care associated infections. The bacteria involved were Escherichia coli in 11 cases, Klebsiella pneumoniae in 10 cases and K. oxytoca in 2 cases. We observed a clinical cure in 19/23 (83%) patients at M-3 and 17/22 (77%) at M-6. Urocultures at M-3 and M-6 were sterile in 13/23 patients (56%) and 9/19 patients (47%), respectively. Urinary colonization was observed in 6/19 (31%) patients with clinical cures at M-3 and 5/14 (36%) patients with clinical cures at M-6. No resistance to cefoxitin was detected. A surgical treatment was required for 7/23 patients (30%).
Cefoxitin-based antibiotic therapy is suitable for difficult-to-treat ESBL-E infections as prostatitis.
We report the first case of Francisella tularensis subsp. holarctica bacteremia after water contamination in France. A 75-year-old man developed septic pneumonic tularemia after a near-drowning ...accident. We highlight the need for a longer incubation time for isolation of F. tularensis from blood cultures.
Celotno besedilo
Dostopno za:
DOBA, IJS, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
6.
Varia Benvegnù, Carlotta; Besle, Sylvain; Bigi, Maëlezig ...
Sociologie du travail (Paris),
02/2023, Letnik:
65, Številka:
1
Journal Article
Varia Barraud de Lagerie, Pauline; Bastin, Gilles; Bergeron, Henri ...
Sociologie du travail (Paris),
06/2020, Letnik:
62, Številka:
1-2
Journal Article
PDF
